Overview

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-nave Patients With Chronic Hepatitis C at KienGiang General Hospital

Status:
COMPLETED

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-nave patients with Chronic Hepatitis C at Kien Giang General Hospital. The study aims to provide affordable treatment options while evaluating the virological response and side effects associated with the therapy

Phase:

PHASE4

Details

Lead Sponsor:

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Treatments:

peginterferon alfa-2a